Blog
RSS FeedPosted by Michael Wonder on 17 Nov 2016
Price discount helps give green light for breast cancer drug pertuzumab
17 November 2016 - NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink ...
Posted by Michael Wonder on 15 Nov 2016
NICE says pancreatic cancer treatment considered not cost effective for routine NHS use
15 November 2016 - The drug pegylated liposomal irinotecan, was not clinically effective enough to justify its high cost, NICE says ...
Posted by Michael Wonder on 13 Nov 2016
Price cuts pave the way for routine access to breast and lung cancer drugs
10 November 2016 - People with breast cancer and lung cancer will have routine access to two life-extending treatments after the ...
Posted by Michael Wonder on 01 Nov 2016
NICE issues draft guidance on the use of ixekizumab
1 November 2016 - NICE has issued draft guidance on the use of Taltz (ixekizumab) for the treatment of patients ...
Posted by Michael Wonder on 01 Nov 2016
Head and neck cancer drug is not cost-effective
1 November 2016 - Cetuximab is not value for money says NICE in new draft guidance. ...
Posted by Michael Wonder on 25 Oct 2016
NICE publishes draft guidance on the use of certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
25 October 2016 - Draft guidance supports the use of both bDMARDs. ...
Posted by Michael Wonder on 21 Oct 2016
New treatment recommended for kidney cancer
20 October 2016 - People with kidney cancer set to benefit from a new innovative immunotherapy, after NICE says it should ...
Posted by Michael Wonder on 20 Oct 2016
Oral Otezla (apremilast) receives positive NICE recommendation for adults with chronic plaque psoriasis
20 October 2016 - Approved by NICE for patients with severe plaque psoriasis as defined by PASI and DLQI greater than ...
Posted by Michael Wonder on 14 Oct 2016
NICE publishes draft guidance on the use of Imbruvica
14 October 2016 - NICE has published draft guidance on the use of Imbruvica (ibrutinib) by patients with Waldenstrom’s macroglobulinaemia. ...
Posted by Michael Wonder on 14 Oct 2016
NICE publishes draft guidance on the use of Opdivo by patients with NSCLC
14 October 2016 - NICE has published draft guidance on the use of Opdivo (nivolumab) by patients with lung cancer. ...
Posted by Michael Wonder on 11 Oct 2016
NICE publishes draft guidance on the use of Otezla on the NHS
11 October 2016 - NICE has published draft guidance on the use of Otelza (apremilast) on the NHS by patients ...
Posted by Michael Wonder on 09 Oct 2016
NICE backs use of Forxiga in triple therapy for diabetes
7 October 2016 - NICE has now published final draft guidelines endorsing NHS use of AstraZeneca's Forxiga for treating type ...
Posted by Michael Wonder on 04 Oct 2016
NICE published draft guidance on a new use for Keytruda
4 October 2016 - NICE has published draft guidance on the use of Keytruda (pembrolizumab) by patients with non-small-cell lung ...
Posted by Michael Wonder on 04 Oct 2016
NICE recommends new drug osimertinib for hundreds of people with lung cancer
4 October 2016 - Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as ...
Posted by Michael Wonder on 03 Oct 2016
NICE says no to daclizumab (Zinbryta)
3 October 2016 - The MS Trust is disappointed that NICE does not intend to recommend that daclizumab (Zinbryta) be made ...